{
    "accountDetails": {
        "accountHasCodexViolations": false,
        "activeDateRanges": [
            {
                "fromDate": "2022-10-13T17:27:38.000+02:00",
                "untilDate": "2024-07-02T00:11:41.000+02:00"
            }
        ],
        "firstPublicationDate": "2022-02-28T14:29:06.000+01:00",
        "inactiveDateRanges": [
            {
                "fromDate": "2024-07-02T00:11:41.000+02:00"
            }
        ],
        "lastUpdateDate": "2023-03-01T19:09:03.000+01:00",
        "registerEntryVersions": [
            {
                "activeUntilDate": "2024-07-02T00:11:41.000+02:00",
                "legislation": "GL2022",
                "registerEntryId": 17406,
                "validFromDate": "2023-03-01T19:09:03.000+01:00",
                "version": 3,
                "versionActiveLobbyist": false
            },
            {
                "legislation": "GL2022",
                "registerEntryId": 12181,
                "validFromDate": "2022-10-13T17:27:38.000+02:00",
                "validUntilDate": "2023-03-01T19:09:03.000+01:00",
                "version": 2,
                "versionActiveLobbyist": true
            }
        ]
    },
    "activeLobbyist": false,
    "activitiesAndInterests": {
        "activity": {
            "code": "ACT_ORGANIZATION",
            "de": "Unternehmen",
            "en": "Company"
        },
        "activityDescription": "CureVac leistet Pionierarbeit bei der Entwicklung und Produktion einer vollkommen neuen Klasse von Medikamenten, die auf dem Botenmolek\u00fcl Messenger-RNA (mRNA) basieren. Das Grundprinzip ist die Verwendung dieses Molek\u00fcls als Datentr\u00e4ger f\u00fcr Informationen, mit deren Hilfe der K\u00f6rper selbst eigene Wirkstoffe f\u00fcr die Bek\u00e4mpfung verschiedener Krankheiten herstellen kann.\r\nDie im Rahmen dieses Registers gemeldeten Aktivit\u00e4ten umfassen sowohl das Informieren von parlamentarischen und institutionellen Entscheidungstr\u00e4gern \u00fcber die M\u00f6glichkeiten der mRNA-Technologie und welchen Beitrag CureVac mit ihr f\u00fcr das Gesamtinteresse der Gesellschaft leistet, als auch das Informieren von CureVac \u00fcber relevante politische Vorhaben, Initiativen und Ma\u00dfnahmen. \r\n",
        "activityOperationType": "BOTH",
        "fieldsOfInterest": [
            {
                "code": "FOI_HEALTH_MEDICINE",
                "de": "Arzneimittel",
                "en": "Medicine"
            },
            {
                "code": "FOI_HEALTH",
                "de": "Gesundheit",
                "en": "Health"
            },
            {
                "code": "FOI_SCIENCE_RESEARCH_TECHNOLOGY",
                "de": "Wissenschaft, Forschung und Technologie",
                "en": "Science, research and technology"
            }
        ],
        "legislativeProjects": []
    },
    "annualReports": {
        "annualReportExists": true,
        "disclosureRequirementsExist": true,
        "locationOfReportPublication": "https://www.curevac.com/investor-relations/finanzberichte/",
        "reportWasPublishedElsewhere": true
    },
    "clientIdentity": {
        "clientsPresent": false
    },
    "codeOfConduct": {
        "ownCodeOfConduct": false
    },
    "donators": {
        "donatorsInformationPresent": false,
        "fiscalYearCompleted": true,
        "fiscalYearEnd": "2022-12",
        "fiscalYearStart": "2022-01",
        "refuseDonatorsInformation": false
    },
    "employeesInvolvedInLobbying": {
        "employeesCount": {
            "from": 1,
            "to": 10
        }
    },
    "financialExpenses": {
        "financialExpensesEuro": {
            "from": 50001,
            "to": 60000
        },
        "fiscalYearCompleted": true,
        "fiscalYearEnd": "2022-12",
        "fiscalYearStart": "2022-01",
        "refuseFinancialExpensesInformation": false
    },
    "legislation": "GL2022",
    "lobbyistIdentity": {
        "address": {
            "city": "T\u00fcbingen",
            "country": {
                "code": "DE",
                "de": "Deutschland",
                "en": "Germany"
            },
            "nationalAdditional1": "CureVac SE",
            "street": "Friedrich-Miescher-Stra\u00dfe",
            "streetNumber": "15",
            "type": "NATIONAL",
            "zipCode": "72076"
        },
        "contactDetails": {
            "emails": [
                {
                    "email": "transparency@curevac.com"
                }
            ],
            "phoneNumber": "+49707198830",
            "websites": [
                {
                    "website": "https://www.curevac.com/"
                }
            ]
        },
        "identity": "ORGANIZATION",
        "legalForm": {
            "code": "LF_SE",
            "de": "Europ\u00e4ische Aktiengesellschaft (SE)",
            "en": "European stock company (SE)"
        },
        "legalFormType": {
            "code": "JURISTIC_PERSON",
            "de": "Juristische Person",
            "en": "Legal person"
        },
        "legalRepresentatives": [
            {
                "academicDegreeBefore": "Dr.",
                "commonFirstName": "Franz Werner",
                "emails": [
                    {
                        "email": "transparency@curevac.com"
                    }
                ],
                "function": "Chief Executive Officer",
                "lastName": "Haas",
                "phoneNumber": "+49707198830"
            },
            {
                "academicDegreeBefore": "Dr.",
                "commonFirstName": "Malte",
                "emails": [
                    {
                        "email": "transparency@curevac.com"
                    }
                ],
                "function": "Chief Operating Officer",
                "lastName": "Greune",
                "phoneNumber": "+49707198830"
            },
            {
                "academicDegreeAfter": "B.Sc",
                "commonFirstName": "Pierre",
                "emails": [
                    {
                        "email": "transparency@curevac.com"
                    }
                ],
                "function": "Chief Financial Officer",
                "lastName": "Kemula",
                "phoneNumber": "+49707198830"
            },
            {
                "academicDegreeAfter": "Ph.D.",
                "commonFirstName": "Antony",
                "emails": [
                    {
                        "email": "transparency@curevac.com"
                    }
                ],
                "function": "Chief Business Officer und Chief Commercial Officer",
                "lastName": "Blanc",
                "phoneNumber": "+49707198830"
            },
            {
                "academicDegreeAfter": "Ph.D.",
                "commonFirstName": "Igor",
                "emails": [
                    {
                        "email": "transparency@curevac.com"
                    }
                ],
                "function": "Chief Scientific Officer",
                "lastName": "Splawski",
                "phoneNumber": "+49707198830"
            },
            {
                "academicDegreeBefore": "Dr.",
                "commonFirstName": "Myriam",
                "emails": [
                    {
                        "email": "transparency@curevac.com"
                    }
                ],
                "function": "Chief Medical Officer & Chief Development Officer",
                "lastName": "Mendila",
                "phoneNumber": "+49707198830"
            }
        ],
        "membersPresent": false,
        "memberships": [
            {
                "membership": "Verband Forschender Arzneimittelhersteller e. V. (vfa)"
            },
            {
                "membership": "BIO Deutschland e. V."
            },
            {
                "membership": "Max-Planck-Gesellschaft zur F\u00f6rderung der Wissenschaften e.V."
            },
            {
                "membership": "Verband der Chemischen Industrie e. V. (VCI)"
            },
            {
                "membership": "Deutsche Gesellschaft f\u00fcr Regulatory Affairs e. V."
            },
            {
                "membership": "Bundesverband Deutsche Startups e. V."
            }
        ],
        "membershipsPresent": true,
        "name": "CureVac SE",
        "namedEmployees": [
            {
                "academicDegreeBefore": "Dr.",
                "commonFirstName": "Marco",
                "lastName": "Rau"
            },
            {
                "academicDegreeBefore": "Dr.",
                "commonFirstName": "Johannes",
                "lastName": "Inama-Sternegg"
            },
            {
                "academicDegreeBefore": "Dr.",
                "commonFirstName": "Markus",
                "lastName": "Bergmann"
            }
        ],
        "namedEmployeesPresent": true
    },
    "publicAllowances": {
        "fiscalYearCompleted": true,
        "fiscalYearEnd": "2022-12",
        "fiscalYearStart": "2022-01",
        "publicAllowances": [
            {
                "description": "F\u00f6rderung zur Unterst\u00fctzung der Entwicklung und Produktion eines COVID-19 Impfstoffkandidaten.",
                "location": "Berlin, Deutschland",
                "name": "Bundesministerium f\u00fcr Bildung und Forschung (BMBF)",
                "publicAllowanceEuro": {
                    "from": 196290001,
                    "to": 196300000
                }
            },
            {
                "description": "3-j\u00e4riger Partnerschaftsvertrag f\u00fcr die pr\u00e4klinische Entwicklung eines Lassavirus-, Gelbfieber- und Tollwutimpfstoffes auf mRNA-Basis. Weiterhin wird in einer Kollaboration ein Impfstoff gegen SARS-CoV-2 entwickelt.",
                "location": "Oslo, Norwegen",
                "name": "Coalition of Epidemic Preparedness Innovations (CEPI)",
                "publicAllowanceEuro": {
                    "from": 680001,
                    "to": 690000
                }
            }
        ],
        "publicAllowancesPresent": true,
        "refusePublicAllowancesInformation": false
    },
    "registerEntryDetails": {
        "annualUpdate": {
            "lastAnnualUpdate": "2023-03-01T19:09:03.000+01:00",
            "updateMissing": false
        },
        "detailsPageUrl": "https://www.lobbyregister.bundestag.de/suche/R002140/17406",
        "pdfUrl": "https://www.lobbyregister.bundestag.de/media/79/81/197582/Lobbyregister-Detailansicht-R002140-2023-03-01_19-09-03.pdf",
        "refusedAnything": false,
        "validFromDate": "2023-03-01T19:09:03.000+01:00",
        "version": 3
    },
    "registerEntryId": 17406,
    "registerNumber": "R002140"
}